Company: RPTX
Filing Date: 2025-07-16
Form Type: 8-K
Source: 0001193125-25-159942
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-07-16
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

On July 15, 2025, Repare Therapeutics Inc. (the “ Company”) entered into an exclusive worldwide license agreement (the “ Agreement”) with Debiopharm International S. A. (“ Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company, regarding the development and commercialization of the Company’s product candidate lunresertib.

Under the Agreement, the Company has granted Debiopharm a worldwide, exclusive, sublicenseable license to develop, manufacture, and commercialize therapeutic products that contains lunresertib as the sole active pharmaceutical agreement (collectively, a “ Repare Product”) or that combine lunresertib with Debio 0123, Debiopharm’s WEE1 inhibitor, and/or any other Wee1 inhibitor controlled by Debiopharm (a “ Combination Product”). Under the terms of the Agreement, the Company will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestone payments, including up to $5 million in potential near-term payments upon the potential achievement of a clinical milestone event, and single-digit royalties on global net sales of Repare Products and Combination Products sold by Debiopharm or its sublicensees. Subject to earlier expiration of the royalty term in specified cases of generic competition, royalties will be paid, on a country-by-countryand Repare Product-by-RepareProduct or CombinationProduct-by-CombinationProduct (as applicable) basis, until, at the earliest, the tenth anniversary of the first commercial sale of such Repare Product or Combination Product in such country.